Jump to content

PubMed RSS Feed - -Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the PRRERCT (Prospective Rosacea Refractory Erythema Randomized Clinical Trial)


Recommended Posts

J Am Acad Dermatol. 2023 Feb 15:S0190-9622(23)00197-4. doi: 10.1016/j.jaad.2023.01.044. Online ahead of print.


BACKGROUND: Patients with refractory erythema of rosacea have limited treatment options.

OBJECTIVE: To evaluate the efficacy and safety of a 12-week course of paroxetine for moderate-to-severe erythema of rosacea.

METHODS: In a multicenter, randomized, double-blinded, placebo-controlled trial, patients with refractory erythema of rosacea were randomly assigned (1:1) to receive paroxetine 25 mg daily or placebo for 12 weeks.

RESULTS: Overall, 97 patients completed the study (paroxetine: 49; placebo: 48). The primary endpoint was the proportion of participants achieving Clinical Erythema Assessment (CEA) success (defined as CEA score of 0, 1 or ≥ 2-grade improvement from baseline) at week 12; this was significantly greater in the paroxetine group than in the placebo group (42.9% vs. 20.8%, P=0.02). Some secondary endpoints were met, such as flushing success with point reductions ≥2 (44.9% vs. 25.0%, p = 0.04) and improvement in overall flushing (2.49 ± 3.03 vs. 1.68 ± 2.27, P=0.047), burning sensation (46.9% vs. 18.8%, P=0.003), and depression (P=0.041). The most reported adverse events associated with paroxetine were dizziness, lethargy, nausea, dyspepsia, and muscle tremors.

LIMITATIONS: Only a single-dosage regimen of paroxetine within a 12-week study was evaluated.

CONCLUSION: Paroxetine is an effective and well-tolerated alternative treatment for moderate-to-severe erythema of rosacea.

PMID:36806645 | DOI:10.1016/j.jaad.2023.01.044

{url} = URL to article

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use